Migraine prophylactic drugs something new under the sun?

Expert Opinion on Investigational Drugs

Volumn 20, Issue 9, 2011, Pages 1201-1210

  Bekkelund, Svein I ^a,b   Alstadhaug, Karl B ^c  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c Nordlandssykehuset ^*  (Norway)

Author keywords

Migraine; New drugs; Prevention; Prophylaxis; Review

Indexed keywords

ACETAZOLAMIDE; ADX10059; ALPHA TOCOPHEROL; ANTICONVULSIVE AGENT; BOTULINUM TOXIN; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CARISBAMATE; ESTROGEN; ETIRACETAM; FROVATRIPTAN; GLUTAMATE RECEPTOR ANTAGONIST; HARKOSERIDE; LAMOTRIGINE; MELATONIN; NARATRIPTAN; OXCARBAZEPINE; PLACEBO; S [2 (1 IMINOETHYLAMINO)ETHYL]HOMOCYSTEINE; SIMVASTATIN; TONABERSAT; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

CELL FUNCTION; CHRONIC DAILY HEADACHE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DATA BASE; DEPRESSION; FOCAL EPILEPSY; HUMAN; MENINGITIS; MENSTRUAL MIGRAINE; MIGRAINE; MIGRAINE WITH AURA; PROTEIN FUNCTION; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSFORMED MIGRAINE;

ANALGESICS; CIRCADIAN RHYTHM; CORTICAL SPREADING DEPRESSION; HUMANS; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASODILATOR AGENTS;

EID: 80051722771     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.601741     Document Type: Review

References (115)

1. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. 2nd edition. Cephalalgia 2004;24(Suppl 1):1-150
2. Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain 2010;11:289-99
3. Lipton RB, Bigal ME, Diamond M. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-9 • This epidemiological study reports important knowledge about the frequency of patients needing prophylactic treatment and undertreatment of prophylactic drugs. (Pubitemid 46184209)
4. Stovner LJ, Hagen K, Jensen R. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193-210 (Pubitemid 46354128)
5. Andlin-Sobocki P, Jonsson B, Wittchen HU, et al. Cost of disorders of the brain in Europe. Eur J Neurol 2005;12:1-27
6. Silberstein SD. For the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62
7. Manack A, Buse DC, Serrano D, et al. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology 2011;76:711-18
8. Alstadhaug KB. Migraine and the hypothalamus. Cephalalgia 2009;29:809-17
9. Levy D. Migraine pain and nociceptor activation - where do we stand? Headache 2010;50:909-16
10. Lambert GA. The lack of peripheral pathology in migraine headache. Headache 2010;50:895-908
11. Zanchin G, Dainese F, Trucco M, et al. Osmophobia in migraine and tension-type headache and its clinical features in patients with migraine. Cephalalgia 2007;27:1061-8 (Pubitemid 47296035)
12. Vingen JV, Pareja JA, Støren O, et al. Phophobia in migraine. Cephalalgia 1998;18:243-9
13. Denuelle M, Boulloche N, Payoux P, et al. A PET study of photophobia during spontaneous migraine attacks. Neurology 2011;76:213-18
14. Doepp F, Schreiber SJ, Dreier JP, et al. Migraine aggravation caused by cephalic venous congestion. Headache 2003;43:96-8 (Pubitemid 36188437)
15. Coppola G, Pierelli F, Schoenen J. Is the cerebral cortex hyperexcitable or hyperresponsive in migraine? Cephalalgia 2007;27:1429-39 (Pubitemid 350150805)
16. Kurosawa M, Messlinger K, Pawlak M, et al. Increase of meningeal blood flow after electrical stimulation of rat dura mater encephali: mediation by calcitoni gene-related peptide. Br J Pharmacol 1995;114:1397-402
17. Ray BS, Wolff HG. Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Arch Surg 1940;41:813-56
18. Wolff HG, Tunis MM, Goodell H. Studies on headache: Evidence of tissue damage and changes in pain sensitivity in subjects with vascular headaches of the migraine type. Trans Assoc Am Physicians 1954;13:229
19. Thalakoti S, Patil VV, Damodaram S, et al. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 2007;47:1008-23 (Pubitemid 47057221)
20. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996;12:560-4 • This is a frequently cited study proposing that meningeal activation contribute to migraine headache. (Pubitemid 26415932)
21. Kristiansen KA, Edvinsson L. Neurogenic inflammation: a study of rat trigeminal ganglion. J Headache Pain 2010;11:485-95
22. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010;6:573-82
23. Somjen GG. Mechanisms for spreading depression and hypoxic spreading-like depolarization. Physiol Rev 2001;81:1065-96 (Pubitemid 32606666)
24. Wessman M, Terwindt GM, Kaunisto MA, et al. Migraine: a complex genetic disorder. Lancet Neurol 2007;6:521-32 (Pubitemid 46734771)
25. Kong LL, Yu LC. Involvement of mu-and delta-opioid receptors in the antinociceptive effects induced by AMPA receptor antagonist in the spinal cord of rats. Neurosci Lett 2006;402:180-3
26. Kuner R. Central mechanisms of pathological pain. Nat Med 2010;16:1258-66
27. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000;123:1703-9 (Pubitemid 30481193)
28. Sanchez Del Rio M, Linera JA. Functional neuroimaging in headaches. Lancet Neurol 2004;3:645-51
29. Welch KMA. Contemporary concepts of migraine pathogenesis. Neurology 2003;61(Suppl 4):S2-8 (Pubitemid 37463356)
30. Blau JN. Migraine: theories of pathogenesis. Lancet 1992;339:1202-7
31. Copola G, pierelli F, Schoenen J. Habituation and migraine. Neurol Learn Mem 2009;92:249-59
32. Noseda R, Kainz V, Jakubowski M, et al. A neuronal mechanism for exacerbation of headache by light. Nat Neurosci 2010;13:239-45 • This study shows that dura-sensitive neurons in the posterior thalamus were modulated by exposure to light via a non-imaging retinal pathway.
33. Alstadhaug KB. Periodicity of migraine. In: Clarke LB. editor. Migraine disorders research trends. Nova Science; New York: 2007. p. 107-44
34. Hattar S, Lucas RJ, Mroskovsky N, et al. Melanopsin and rod-cone photoreceptive system account for all major accessory visual functions in mice. Nature 2003;424:76-81 (Pubitemid 36834844)
35. Gooley JJ, Lu J, Fisher D, Saper CB. A broad role of melanopsin in nonvisual photoreception. J Neurosci 2003;23:7093-06
36. Somerville BW. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology 1972;22:355-65
37. Facchinetti F, Sances G, Borella P, et al. Magnesium prophylaxis of menstrual migraine. Effects on intracellular magnesium. Headache 1996;31:298-301
38. Mauskop A. Editorial: evidence linking magnesium deficiency to migraines. Cephalalgia 1999;19:766-7
39. Sparaco M, Feleppa M, Lipton RB, et al. Mitochondrial dysfunction and migraine: evidence and hypotheses. Cephalalgia 2005;26:361-72
40. MacGregor EA, Brandes JL, Silberstein S, et al. Safety and tolerability of short-term preventive frovatriptan: a combined analyses. Headache 2009;49:1298-14
41. Goadsby PJ, Ferrari MD, Csanyi A, et al. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia 2009;29:742-50
42. Hauge AW, Asghar MS. Schytz, et al. Effects of tonabersat on migraine with aura: a randomised double-blind, placebo-controlled crossover study. Lancet Neurol 2009;8:718-23 • This is the first RCT trial showing the effect of tonabersat on migraine with aura, but not in migraine without aura.
43. Cady RK, Mathew N, Diener HC, et al. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Headache 2009;49:216-26
44. ®) for migraine without aura. Headache 2011;51:52-63
45. Couch JR. Amitriptyline versus placebo study group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 2011;51:33-51
46. Silberstein SD, Berner T, Tobin J, et al. Scheduled short-term prevention with frovatriptan for migraine occuring exclusively in association with menstruation. Headache 2009;49:1283-97
47. Alstahaug KB, Odeh F, Salvesen R, Bekkelund S. Prophylaxis of migraine with melatonin. A randomized controlled trial. Neurology 2010;75:1527-32
48. Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker. A randomized controlled trial. JAMA 2003;289:65-9 (Pubitemid 36026279)
49. Mulleneers WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalgia 2008;28:585-97 • This is a comprehensive evidence-based review of prophylactic drugs for migraine. (Pubitemid 351614940)
50. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52:281-6
51. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalagia 1997;17:103-8 (Pubitemid 27166264)
52. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;458:1652-9 (Pubitemid 34602897)
53. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;291:965-73 (Pubitemid 38543754)
54. Silberstein SD, Neeto W, Schmitt J, et al. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004;61:490-5 (Pubitemid 38923736)
55. Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis - results from a placebocontrolled trial with propranolol as an active control. J Neurol 2004;251:943-50 (Pubitemid 39119312)
56. Vikelis M, Rapoport AM. Role of antiepileptic drugs as preventive agents for migraine. CNS Drugs 2010;24:21-33
57. Gode S, Celebisoy N, Karazli T, et al. Clinical assessment of topiramate therapy in patients with migrainous vertigo. Headache 2010;50:77-84
58. Edvinsson L. Linde Mattias. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet 2010;376:645-55
59. Di Trapani G, Mei D, Marra C, et al. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ter 2000;151:145-8 (Pubitemid 30482218)
60. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001;41:119-28 (Pubitemid 32209899)
61. Available from: http://clincaltrials.pharmaceuticals-business-review.com/ news/migraine-drug-gabapentin-enacarbil-fails-in-phase-2b-study-gsk-xenoport- 100708#
62. Krusz JC, Albright JP. Lacosamide in the treatment of chronic headache and migraine disorders. 52th annual scientific meeting of the American headache society; Los Angeles; June 2010, PO-104
63. Available from: www.ucb.com
64. Pizza V, Busillo V, Agresta A, et al. Elderly patients with migraine: an open-label study on propohylaxis therapy with levetiracetam. Cent Nerv Syst Agents Med Chem 2011. [Epub ahead of print]
65. Villani V, Ciuffoli A, Prosperini L, et al. Zonisamide for migraine prophylaxis in topiramate-intolerant patients: an observational study. Headache 2011;51:287-91
66. Smith MI, Read SJ, Chan WN, et al. Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453. Cephalagia 2000;20:546-53 (Pubitemid 32269472)
67. Hadjikhani N, Sanchez Del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 2001;98:4687-92 (Pubitemid 32295037)
68. Garza I. Tonabersat: a cortical spreading depression inhibitor as potential pharmacologic prophylaxis in migraine with aura. Curr Neurol Neurosci Rep 2010;10:7-9
69. Read SJ, Smith MI, Hunter AJ, et al. SB-220453, a potential novel antimigraine compound, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat. Cephalalgia 1999;20:92-9 (Pubitemid 32269515)
70. Christiansen I, Thomsen LL, Daugaard D, et al. Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalagia 1999;19:660-7 (Pubitemid 29465917)
71. Olesen J. Nitric oxide-related drug targets in headache. Neurotherapeutics 2010;7:183-90
72. Høivik HO, Laurijssens BE, Harnisch LO, et al. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia 2010;30:1458-67
73. Rajanayagam MAS, Li CG, Rand MJ. Differential effects of hydroxocobalamin on NO-mediated relaxations in rat aorta and anococcygeus muscle. Br J Pharmacol 1993;108:3-5 (Pubitemid 23007398)
74. van der Kuy PH, Merkus FW, Lohman JJ, et al. Hydroxocobalamin, a nitric oxide scavenger, in the prophylaxis of migraine: an open, pilot study. Cephalalgia 2002;22:513-19 (Pubitemid 36609344)
75. Pollack MA, French JH. Hypothesis: glutamic acid in migraine. Headache 1975;15:114-17
76. Andreou AP, Goadsby PJ. Therapeutic potential of novel glutamate receptor antagonist in migraine. Expert Opin Investig Drugs 2009;18:789-803
77. Marin JC, Goadsby PJ. Glutamatergic fine tuning with ADX-ø10059: a novel therapeutic approach for migraine? Expert Opin Drugs 2010;19:555-61
78. Kalsbeek A, Palm IF, La Fleur SE, et al. SCN outputs and the hypothalamic balance of life. J Biol Rhythms 2006;21:458-69 (Pubitemid 44706827)
79. Alstadhaug KB, Salvesen R, Bekkelund S. 24-hour distribution of migraine. Headache 2008;48:95-100
80. Alstadhaug K, Salvesen R, Bekkelund S. Insomnia and circadian variation of attacks in episodic migraine. Headache 2007;47:1184-8 (Pubitemid 47457767)
81. Peres MF, Zukerman E, Da Cunha Tanuri F, et al. Melatonin 3 mg is effective for migraine prevention. Neurology 2004;63:757
82. Wilhelmsen M, Amirian I, Reiter RJ, et al. Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res 2011. [Epub ahead of print]
83. Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 1989;165:251-8 (Pubitemid 19181793)
84. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in male British doctors. BMJ 1988;296:313-36
85. Buring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAMA 1990;264:1711-13 (Pubitemid 20324354)
86. Kirthi V, Derry S, Moore RA, et al. Review: Aspirin reduces acute migraine pain in adults. Cochrane Database Syst Rev 2010 (9): CD008041
87. Ziegler DK, Ellis DJ. Naproxen in prophylaxis of migraine. Arch Neurol 1985;42:582-4 (Pubitemid 15033097)
88. Welch KMA, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. Neurology 1985;35:1304-10 (Pubitemid 15021591)
89. Szekely B, Meeryman S, Post G. Prophylactic effects of naproxen sodium on perimenstrual headache: a double blind, placebo-controlled study. Cephalalgia 1989;9:452-3 (Pubitemid 20166771)
90. McCulloch J, Uddman R, Kingman TA, Edvinsson L. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci USA 1986;83:5731-5 (Pubitemid 16001291)
91. Levy D, Burstein R, Strassman AM. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 2005;58:698-705 • This experimental study demonstrates that vasodilation caused by CGRP do not promote activation of meningeal nociceptors. (Pubitemid 41552545)
92. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-7 (Pubitemid 20244522)
93. Ottosson A, Edvinsson L. Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia 1997;17:166-74 (Pubitemid 27257341)
94. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350:1104-10 (Pubitemid 38298990)
95. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372:2115-23
96. Fernandez-Mayoralas DM, Fernandez-Jaen A, Munoz-Jareno N, et al. Migraine symptoms related to the percutaneous closure of an ostium secundum atrial septal defect: report of four paediatric cases and review of the literature. Cephalalgia 2007;27:550-6 (Pubitemid 46848921)
97. Victor TW, Hu X, Campbell JC, et al. Migraine prevalence by age and sex in the United States: a life span study. Cephalalgia 2010;30:1065-72
98. Couturier EG, Bomhof MA, Neven AK, et al. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 2003;23:302-8 (Pubitemid 36577949)
99. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology 2004;63:351-3 (Pubitemid 38971141)
100. Stewart WF, Lipton RB, Chee E, et al. Menstrual cycle and headache in a population sample of migraineurs. Neurology 2000;55:1517-23
101. Pringsheim T, Davenport WJ, Dodick D. Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology 2008;22:1555-63 (Pubitemid 351589510)
102. Brandes JL, Poole AC, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia 2011;29:1133-48
103. Ziaei S, Kazemenajad A, Sedighi A. The effect of vitamin E on the treatment of menstrual migraine. Med Sci Monit 2009;15:CR16-19
104. Lance JW, Curran DA. Treatment of chronic tension headache. Lancet 1964;1:1236-9
105. Jackson JL, Shimeall W, Sessums L, et al. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ 2010;341:c5222
106. Shuhendler AJ, Lee S, Siu M, et al. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy 2009;29:784-91
107. Le Doare K, Akerman S, Holland PR. Occipital afferent activation of second order neurons in the trigeminocervical complex in rat. Neurosci Lett 2006;403:73-7 (Pubitemid 43963256)
108. Ashkenazi A, Levin M. Greater occipital nerve block for migraine and other headaches. Is it useful? Curr Pain Headache Rep 2007;11:231-5 (Pubitemid 46851253)
109. Claudio A, Caputi MD, Vincenzo F. Therapeutic blockade of greater occipital and supraorbital nerves in migraine patients. Headache 1997;37:174-9
110. Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes - prolonged effects from a single injection. Pain 2006;122:126-9
111. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010;6:573-82
112. Kai-Kai MA, Howe R. Glutamate-immunoreactivity in the trigeminal and dorsal root ganglia, and intreaspinal neurons and fibres in the dorsal horn of the rat. Histochem J 1991;23:171-9
113. Andreou AP, Goadsby PJ. Therapeutic potential of novel glutamate receptor antagonists in migraine. Expert Opin Investig Drugs 2009;18:789-803
114. National Institutes of Health. NINDS Clinical Research Center. Chronic Migraine Treatment Trial. Available from: www.ninds.nih.gov/disorders/clinical- trials/NCT00772031.htm
115. Holroyd KA, Cottrell CK, O'Donnell FJ, et al. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ 2010;341:c.4871